Biotech Values

[go seek]

Projecting MNTA’s net profits:

my point is if they are not cash flow positive yet they are getting close.

>> @ 1:53 in the 20 Sept UBS call, Wheeler said "I am pleased to report our cash balance (of $68.7M) is growing... this is something I am unaccustomed to talking about during the last 4 years."



also ref #msg-53629665

"Until NVS has recouped its Lovenox development costs (which will take 2-3 quarters), the amount MNTA will report on the top line of its income statement will be half the above amount, which comes to $30M per quarter. This ought to easily outweigh the $13M per quarter that MNTA has been burning in recent quarters (#msg-52864485) and yield a quarterly profit in the $15-20M range during the first 2-3 quarters."